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Insufficient liver function is the single, most important determi-
nant of outcome after a major liver resection. At the same time,
there is not one liver test that reflects all components of the diverse
spectrum of liver function.1 Two papers2,3 in this issue of HPB deal
with the prediction of post-hepatectomy liver failure (PHLF), a
dramatic event that is difficult to manage as effective substitution
of liver function by means of liver assist devices including the
bioartificial liver, is still lacking. PHLF should be the equation
of failure to predict accurately liver functional reserve pre-
operatively, given the extent of the resection considered necessary
to remove all of the tumour and the quality of liver parenchyma.
The reason that pre-operative assessment of liver function might
fail to predict PHLF is that pre-existing liver injury may be under-
estimated on the basis of CT volumetric studies. Furthermore,
many patients referred for a resection have undergone exten-
sive chemotherapy with consequent steatotic or microvascular
changes of their livers. Even when applying dynamic, quantitative
liver function tests in the pre-operative work-up, intra-operative
circumstances such as deviation of the operative plan or inadvert-
ent massive blood loss, are factors influencing post-operative liver
function that cannot be taken into account pre-operatively. The
risk assessment of PHLF in the pre-operative setting and a pre-
diction of PHLF after a resection, are therefore distinct. Whereas
pre-operative risk assessment is used to select patients amenable
to resection, prediction of PHLF is used to anticipate treatment,
albeit limited to largely supportive care. A salient point is that
patients with PHLF unresponsive to therapy seldom are candi-
dates for salvage (cadaveric) liver transplantation, as the tumour
burden underlying these extensive resections usually by far
exceeds accepted criteria for liver replacement.
In both papers, from Leeds2 and Warsaw,3 PHLF prediction is
based on serum liver function tests (LFTs). The term LFT is con-
fusing in the present context as these parameters do not all reflect
liver function. The serum transaminase levels [aspartate transami-
nase (AST) and alanine transaminase (ALT)] are liver damage
parameters, and although the extent of hepatocellular necrosis
will obviously impact liver functional reserve, they are not liver
function tests per se. Perhaps for this reason, AST came out as
significant predictor of 90-day mortality in the analysis of the
Warsaw group. The International Normalized Ratio (INR) on the
other hand is a functional parameter as plasma levels of coagula-
tion factors are correlated with synthetic activity of the liver.
Plasma bilirubin, alone or in combination with INR, was identi-
fied as a strong predictor of PHLF. These blood tests are quite
familiar to us as they appear in various, widely used clinical
scoring systems such as the Child–Pugh score4 and the MELD
(model for end-stage liver disease) score5 in the assessment of
patients with cirrhosis. Also in the ‘50-50 criteria’ proposed by the
Beaujon group in Paris6 to predict PHLF, plasma bilirubin and
INR are the key parameters along with a time dimension, i.e. the
fifth post-operative day.
The plasma bilirubin concentration is a function of uptake,
conjugation and excretion of bilirubin by the liver and increased
plasma levels indicate serious malfunction of the liver.1 The
authors of both papers have elegantly shown that plasma
bilirubin, alone or in combination with INR, is an early predictor
of PHLF.2,3 Although specificity is low, elevated bilirubin on the
first postoperative day was shown to be a harbinger of impending
PHLF, as defined by the International Study Group for Liver Sur-
gery.7 As such, it will provide a valuable factor in the clinical
picture of a patient who after a major liver resection, develops
drowsiness with derangement of coagulation parameters and
increased plasma lactate levels. Except for intensive care unit
admission, supplementation of deficient substances as coagula-
tion factors and albumin, as well as broad antibiotic coverage to
compensate for the loss of Kupffer cell function, there is little that
can be offered in the treatment of these patients. In a series of
patients with PHLF treated with the Molecular Adsorbent Recir-
culating System (MARS) device, our group observed transient
clinical and biochemical improvement, but eventually, all patients
died because of septic complications.8 In my view, active interven-
tions in PHLF are started too late to exert any benefit as recovery
of the patient mainly relies on the ability of the remnant liver to
regenerate, thereby catching up function. In spite of the strong
trigger for regeneration after extensive liver resection, hepatocel-
lular function and proliferation are suppressed by the toxic load
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with which the already small liver remnant has to cope. Many
years spent in the development of a bioartificial liver has taught us
that hepatocytes fail to thrive and to function optimally when
exposed to the plasma of patients in liver failure.9 Early treatment
with liver support devices to reduce the toxic load to facilitate
regeneration of the remnant liver therefore seems crucial.
Although ideally, one might want to use true quantitative func-
tional liver tests such as the indocyanine green clearance test or
hepatobiliary scintigraphy to define liver functional reserve after
extensive liver resection, measurement of plasma bilirubin on the
first post-operative day provides a simple laboratory test to iden-
tify patients at an increased risk of developing PHLF.
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